Lorlatinib

8 trials 2 recruiting LOncology

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

2 Recruiting

6 Completed trials

6 Sponsors

10 Countries

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 5 Phase IV: 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 3 Non-small cell lung cancer stage IV 3 Non-small cell lung cancer stage IIIB 1 Non-small cell lung cancer metastatic 1

Sponsors using this IMP

Pfizer Inc. 3 Centro Di Riferimento Oncologico Di Aviano 1 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Intergroupe Francophone De Cancerologie Thoracique 1 Universita Degli Studi Di Milano Bicocca 1

All trials

8 total

A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based c… Recruiting

2023-506714-43-00 Phase II 1 country Centro Di Riferimento Oncologico Di Aviano
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Lorlatinib Continuation Study Ended

2023-508952-21-00 Phase IV 2 countries Pfizer Inc.
Master Protocol for Avelumab Continuation Study. Ended

2023-509466-38-00 Phase III 7 countries Pfizer Inc.
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Ended

2024-512028-12-00 Phase II 1 country Intergroupe Francophone De Cancerologie Thoracique
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancer Ended

2023-509169-19-00 Phase III 8 countries Pfizer Inc.
Clinical trial with the drug lorlatinib in patients affected by a lymphoma that expresses the protein ALK, previously treated with ALK inhib… Ended

2025-520788-42-00 Phase II 1 country Universita Degli Studi Di Milano Bicocca

Showing 1–8 of 8 trials

← All drugs A–Z